The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation

Kazuhiko Ikeda1,2, Koki Ueda1, Takahiro Sano1, Kazuei Ogawa1, Takayuki Ikezoe1, Yuko Hashimoto3, Soji Morishita4, Norio Komatsu5, Hitoshi Ohto2 and Yasuchika Takeishi6

Abstract

Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations.

Key words: myelofibrosis, polycythemia vera, thrombocytopenia, ruxolitinib, JAK2 exon 12 mutation

(Intern Med 56: 1705-1710, 2017) (DOI: 10.2169/internalmedicine.56.7871)

Introduction

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), are characterized by the proliferation of mature blood cells and extramedullary hematopoiesis (1). In addition to PMF, secondary myelofibrosis (MF) occasionally arises from PV (post-PV MF) and ET. Mutations in JAK2 (Janus Kinase 2), MPL (MPL protooncogene, thrombopoietin receptor), and CALR (calreticulin) activate the JAK-STAT (signal transducer and activator of transcription) signaling pathway, which drives proliferative hematopoiesis in the MPNs (2). JAK2V617F is found in more than 90% of PV patients and approximately half of ET and PMF patients (3-6), whereas JAK2 exon 12 mutations are rarely - but almost exclusively - detected in PV (7, 8). MPNs also show mutations in epigenetic modifiers including DNMT3A (DNA Methyltransferase 3a), TET2 (Tet Methylcytosine Dioxygenase 2), ASXL1 (Additional Sex Combs Like 1), and EZH2 (Enhancer of Zeste Homolog 2) (9). These epigenetic-related mutations are detected in MF more frequently than other types of MPNs and may contribute to the disease progression and shorter survival of MF patients (10-12).

PMF is well known to have a poor prognosis (12, 13). Recently, patients with PV and ET have also been reported to have a reduced life expectancy (14, 15). The disease-related complications of PV that may reduce survival rates include thrombosis, hemorrhagic events, and evolution to acute leukemia or post-PV MF (16). The cumulative incidence of MF evolution at 15 years after the diagnosis of PV has been reported to approximately 6-14%, and median survival term of patients with post-PV MF is less than 6 years. Recently, Passamonti et al. (17) demonstrated that the rates of MF evolution and survival in PV patients with JAK2 exon 12 mutations were similar to those with JAK2V617F; however, these two mutational subtypes show distinct clini-
cal phenotypes at the clinical onset (7, 8). PV patients with \textit{JAK2}^{V617F} show leukocytosis and thrombocytosis as well as erythrocytosis, while PV patients carrying \textit{JAK2} exon 12 mutations mainly show isolated erythrocytosis. Thus, PV patients with \textit{JAK2} exon 12 mutations or \textit{JAK2}^{V617F} should receive meticulous care in terms of disease-related complications, including post-PV MF.

Ruxolitinib is an oral JAK1/2 inhibitor that targets the JAK-STAT signaling pathway. The Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT)-I and COMFORT-II studies first demonstrated the rapid and durable reduction of splenomegaly and disease-related symptoms in patients with intermediate-2 or high-risk MF in comparison to patients who received placebo and the best available therapy (18, 19). Ruxolitinib was also superior to the best available therapy in controlling the hematocrit levels in PV patients who could not tolerate or who showed an insufficient response to hydroxyurea (20). Despite being an unintended endpoint, the further analysis of the COMFORT data suggested that ruxolitinib improved the overall survival (21, 22) and reduced the allele burden of \textit{JAK2}^{V617F} (23) in MF. However, reports showing the histological improvement of bone marrow (BM) fibrosis following ruxolitinib treatment are extremely rare (24-26). Thus far, the role of ruxolitinib in PV or post-PV MF in patients with \textit{JAK2} exon 12 mutations is almost unknown.

We herein describe a case in which ruxolitinib treatment led to a reduction of BM fibrosis with improvements in thrombocytopenia and erythrocytosis in a patient with post-PV MF who carried a \textit{JAK2} exon 12 mutation.

Case Report

A 77-year-old Japanese man was referred to us because of erythrocytosis and thrombocytopenia with fatigue, weight loss (3 kg over 6 months), and splenomegaly (Fig. 1A). Laboratory tests showed peripheral erythrocytosis with 6.75 x10^{12}/L erythrocytes, 18.8 g/dL hemoglobin, and 56.8% hematocrit; thrombocytopenia with 81 x10^{9}/L platelets; elevated serum LDH at 347 U/L [reference interval (RI) ≤226]; and decreased plasma erythropoietin with 1.4 mIU/mL (RI: 4.2-23.7). Although the patient’s leukocyte count was normal (4.9 x10^{9}/L), metamyelocytes were present in the peripheral blood; myeloblasts and erythroblasts were not detected. A BM biopsy demonstrated hypercellularity with trilineage growth and reticulin fibrosis (Fig. 2A). No chromosomal abnormalities were found in the BM cells. Mutational assays (27-29) did not detect \textit{JAK2}^{V617F}, \textit{MPL}^{W515K/L}, or \textit{CALR} exon 9 mutations in the peripheral leukocytes. However, the patient was diagnosed with post-PV MF based on the detection of endogenous erythroid colony (EEC) formation and a known \textit{JAK2} exon 12 mutation ([\textit{JAK2}^{H538QK539L} (8)] (Fig. 3), along with erythrocytosis, a decreased erythropoietin level (1.4 mIU/mL; RI, 4.2-23.7), and BM hypercellularity. The previous data that were available also showed that he first developed erythrocytosis and thrombocytopenia at 2 years before his diagnosis (Fig. 4). Ruxolitinib (5 mg, twice daily) was administered for the treatment of post-PV MF; this provided rapid histological (Fig. 2B) and hematological (Fig. 4) responses with an increase in platelets and a reduction of erythrocytosis. Moreover, the patient’s splenomegaly (Fig. 1B) improved, and his body weight recovered to baseline. These responses are ongoing at 16 months since the initiation of treatment.

Histopathological findings

Before treatment, hypercellularity and MF-2 grade reticulin fibrosis (30) was seen throughout the BM (Fig. 2A). A BM biopsy performed at 10 months after the initiation of treatment showed a reduction in the cellularity and MF-0 to MF-1 grade fibrosis in approximately 70% of the BM, whereas 30% remained hypercellular with MF-2 grade fibrosis (Fig. 2B).

Target sequencing

The target sequencing of the Human Myeloid Neoplasms Panel (Qiagen, Hilden, Germany; Catalog No. NGHS-003X) was performed using a next-generation sequencer (MiSeq;
The histopathological findings of the bone marrow specimen. (A) Diffuse trilineage proliferation with MF-2 fibrosis was present in whole marrow upon the diagnosis of post-PV MF. (B) Hypercellularity with fibrosis was significantly reduced and still partly present (*) at 8 months after starting the initiation of ruxolitinib treatment. Hematoxylin and Eosin staining and Gomori’s silver impregnation (silver) are shown.

Illumina, San Diego, CA, USA). This identified a known somatic mutation, \textit{DNMT3A}R882C (31), in addition to \textit{JAK2}H538QK539L in the peripheral leukocytes. While the allele burden of \textit{JAK2}H538QK539L showed a slight reduction (56.3% to 48.5%) at 10 months after the initiation of treatment, that of \textit{DNMT3A}R882C barely changed (30.5% to 29.9%).

Discussion

In the present case, treatment with ruxolitinib resulted in a major improvement of thrombocytopenia and erythrocytosis and a reduction of fibrosis in a patient with post-PV MF associated with \textit{JAK2} exon 12 mutation. In a phase 2 clinical trial for thrombocytopenic MF with a platelet count of 50-100x10^9/L, 7 of 50 patients showed increased platelet counts ≥15x10^9/L (in comparison to baseline) at week 24 (32). Younger age, a recent diagnosis, a low-risk classification in the dynamic international prognostic scoring system, primary disease (PMF), and low neutrophil count were associated with platelet count increases; the report did not mention the \textit{JAK2} mutational status. The characteristics of our patient might have been different because the low neutrophil count was the only comparable variable. Recently,
Figure 3. Evidence of underlying PV. (A) Burst-forming unit erythroid (BFU-E) colonies grown from $1 \times 10^6$ peripheral blood mononuclear cells (PBMCs) with the indicated concentrations of erythropoietin (EPO) were counted using an inverted microscope. Some BFU-E colonies were seen in this case (dark gray) in the absence (0 U/mL) or presence of low-concentration EPO (0.3 U/mL). In contrast, in the PBMCs of 2 healthy controls, BFU-E colonies barely grew at 0 and 0.3 U/mL EPO (light gray). The mean colony numbers of 2 plates are shown. (B) The Sanger sequence indicated substitutions of nucleotides that corresponded to JAK2H538QK539L.

Figure 4. The clinical course. At 3 years before the diagnosis of post-PV MF (year X-3), the patient’s peripheral blood cell count was normal. This patient had already developed erythrocytosis and thrombocytopenia at 2 years before the diagnosis (year X-2). In year X, after starting ruxolitinib treatment, his hemoglobin level (Hb) and platelet count (PLT) rapidly normalized; this effect has persisted for 16 months since the initiation of treatment. The patient’s white blood cell count (WBC) has been stable.

Platelet increases have also been reported in two patients with thrombocytopenic post-PV MF with JAK2V617F (33). These studies and our present case indicate that ruxolitinib is a treatment option for thrombocytopenic post-PV MF regardless of the JAK2 mutation type.

The mechanisms by which ruxolitinib increases the platelet count in patients with thrombocytopenic MF remain unclear; however, the reduction in splenomegaly, the improvement in the BM microenvironment through decreased inflammatory cytokine production and the preferential suppression of the neoplastic clones have been suggested as possible causes (33). In our present patient, we observed a reduction in the size of the spleen (Fig. 1), which is a major effect of ruxolitinib in many cases (18, 19). A partial, but
significant amelioration of fibrosis was also observed (Fig. 2), which is a rare effect of ruxolitinib (24-26). The recovery of producible thrombopoiesis thanks to the amelioration of fibrosis possibly contributed to the increase in his platelet count. In the present case, it is unclear whether ruxolitinib improved the BM microenvironment or eliminated a neoplastic clone in our case. However, the environmental improvement is likely to be more important than the elimination of a neoplastic clone, because his disease-related symptoms, which were probably due to inflammatory cytokines (34), disappeared with ruxolitinib. In contrast, only a slight reduction was seen in the allele burden of the mutant JAK2 our patient. At this point, the mutant for a durable effect of ruxolitinib in the future care of patients (23). Thus, the gradual reduction in the allele burden of the mutant JAK2 for a durable effect of ruxolitinib in the future care of patients (23). Thus, the gradual reduction in the allele burden of the mutant JAK2 our patient. At this point, the mutant JAK2 exon 12. However, the long-term follow-up of COMFORT-I recently revealed major molecular responses determined by the allele burden of JAK2V617F in some MF patients (23). Thus, the gradual reduction in the allele burden of the mutant JAK2 exon 12 may have also be important for a durable effect of ruxolitinib in the future care of our patient. At this point, the mutant DNMT3A remains at a very stable allele burden relative to the mutant JAK2 exon 12. This is probably consistent with a finding that DNMT3A, ASXL1, and EZH2 mutations were correlated with poor responses to ruxolitinib in MF (35). In the present case, the changes in the allele burdens of the mutants suggest that ruxolitinib can slightly decrease the numbers of clones that carry a JAK2 exon 12 mutation alone, but not clones that carry both JAK2 exon 12 and DNMT3A mutations or DNMT3A mutations alone. Our patient presented with thrombocytopenia when he first showed erythrocytosis. In addition, MF-2 fibrosis was found at only two years after the development of erythrocytosis; however, a cohort study indicated that MF occurred at least 20 years after the onset of PV in most patients with JAK2 exon 12 mutations (17). Thus, it is difficult to exclude PMF in our present patient; however, we are of the opinion that it represents a case of post-PV MF because EEC formation and JAK2 exon 12 mutations are usually exclusive to PV.

It has been reported that older age, leukocytosis, splenomegaly, thrombocytosis, a masked-PV phenotype (PV characteristics with lower hemoglobin levels than criteria targets), a high JAK2V617F allele burden, and chromosome 12 abnormalities are associated with the evolution of MF in PV (16, 36). Among these factors, only old age and splenomegaly fit our case, and the cause of his MF evolution remains unknown. HMGA2 is located on chromosome 12; thus, since our previous study (29) and the studies of other authors (37-39) have reported that HMGA2 is highly expressed in the hematopoietic cells from the vast majority of MF patients, we measured the HMGA2 mRNA level in his granulocytes. The expression of HMGA2 mRNA in his granulocytes at the time of the diagnosis was 3-fold higher than that in healthy controls, as well as the MF patients in our previous study (29). However, it is unclear whether HMGA2 contributes directly to the evolution of MF, because the overexpression of HMGA2 causes MPN-like hematopoiesis without MF in mouse models (40, 41).

To our knowledge, this is the first reported case in which post-PV MF was ameliorated by ruxolitinib leading to a resolution of thrombocytopenia in a patient with a JAK2 exon 12 mutation. The mechanisms underlying the improvement of both MF and thrombocytopenia should be studied further; however, we should at least consider the use of ruxolitinib in the treatment of thrombocytopenic MF, including post-PV MF in patients with JAK2 exon 12 mutations.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We are grateful to Dr. A. Shichishima-Nakamura, Ms. M. Takasaki, and Ms. A. Haneda for their assistance. This study is a part of the genomic study approved by the Ethics Review Board of Fukushima Medical University (No. 1242), which is guided by local policy, national law and the World Medical Association Declaration of Helsinki.

References

1. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 112: 2190-2198, 2008.
2. Skoda RC, Duck A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol 43: 599-608, 2015.
3. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148, 2005.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790, 2005.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythaemia vera, essential thrombocthyemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005.
7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythaemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459-468, 2007.
8. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 86: 668-676, 2011.
9. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12: 599-612, 2012.
10. Kameda T, Shide K, Yamaji T, et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125: 304-316, 2015.
11. Sashida G, Iwama A. Epigenetic regulation of hematopoiesis. Int J Hematol 96: 405-412, 2012.
12. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 27: 1861-1869, 2013.
13. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392-397, 2011.
14. Hultcrantz M, Kristinsson SY, Andresson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30: 2995-3001, 2012.
15. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly essential thrombocythemia, polycythemia vera and myelofibrosis. Blood 124: 2507-2513, 2014.
16. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 5: e366, 2015.
17. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117: 2813-2816, 2011.
18. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799-807, 2012.
19. Harrison C, Kiladjian J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.
20. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426-435, 2015.
21. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98: 1865-1871, 2013.
22. Cervantes F, Vannucchi A, Kiladjian J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122: 4047-4053, 2013.
23. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126: 1551-1555, 2015.
24. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98: 1872-1876, 2013.
25. Harrison C. JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Haematologica 100: 409-411, 2015.
26. Cervantes F. How I treat myelofibrosis. Blood 124: 2635-2642, 2014.
27. Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 100: e46-e48, 2015.
28. Edahiro Y, Morishita S, Takahashi K, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 99: 625-634, 2014.
29. Harada-Shirado K, Ikeda K, Ogawa K, et al. Dysregulation of the MIRLET7/HMG2A axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br J Haematol 168: 338-349, 2015.
30. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 25: 1193-1202, 2012.
31. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25: 1217-1219, 2011.
32. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6: 81, 2013.
33. Gruenwald MR, Spivak JL. Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis. J Clin Oncol 34: e38-e40, 2016.
34. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29: 1356-1363, 2011.
35. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126: 790-797, 2015.
36. Benton CB, Tanaka M, Wilson C, et al. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res 39: 419-423, 2015.
37. Andrieux J, Demory JL, Dupriez B, et al. Dysregulation and overexpression of HMG2A in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39: 82-87, 2004.
38. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’ tumor gene 1 (WT1). Stem Cells 25: 165-173, 2007.
39. Bruchova H, Merkerova M, Prchal JT. Abrupt increase of microRNA in polycythemia vera. Haematologica 93: 1009-1016, 2008.
40. Ikeka K, Mason PJ, Bessler M. 3’UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 117: 5860-5869, 2011.
41. Oguro H, Yuan J, Tanaka S, et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med 209: 445-454, 2012.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).